A Rough Guide to Metabolite Identification Using High Resolution Liquid Chromatography Mass Spectrometry in Metabolomic Profiling in Metazoans

David G. Watson

Abstract: Compound identification in mass spectrometry based metabolomics can be a problem but sometimes the problem seems to be presented in an over complicated way. The current review focuses on metazoans where the range of metabolites is more restricted than for example in plants. The focus is on liquid chromatography with high resolution mass spectrometry where it is proposed that most of the problems in compound identification relate to structural isomers rather than to isobaric compounds. Thus many of the problems faced relate to separation of isomers, which is usually required even if fragmentation is used to support structural identification. Many papers report the use of MS/MS or MS^2 as an adjunct to the identification of known metabolites but there are a few examples in metabolomics studies of metazoans of complete structure elucidation of novel metabolites or metabolites where no authentic standards are available for comparison.

1. Introduction

This article examines the application of liquid chromatography high resolution mass spectrometry (LCHRMS) in metabolomic profiling in relation to metabolite identification. The review focuses on metabolomics in metazoans since the issues with regard to identification are different to the issues with regard metabolite identification in plants and microbes, but not necessarily simpler. On the one hand the diversity of chemical structures in plants and microbes is huge in comparison with metazoans but on the other these metabolites can often be obtained in large quantities and are amenable to isolation and characterisation by nuclear magnetic resonance spectroscopy (NMR). Identification of metabolites can be a problem in mass spectrometry based metabolomics [1-7] but sometimes the issue is made to seem more difficult than it actually is. If the goal of a metabolomics study is to monitor well characterised metabolites for instance in disease monitoring, then low resolution mass spectrometry might be more appropriate since the target compounds are known and tandem mass spectrometry is a method which is highly standardised with regard to being able to obtain quantitative accuracy. Some research groups have set up more specific biomarker screens based on low resolution tandem mass spectrometry where a large number of standard compounds have been used to standardise the methods [8-13]. However, for many research groups biomarker discovery remains a more general screening operation. Gas chromatography mass spectrometry (GC-MS) remains a widely used general screening process and is very effective for the wide range of compounds which are either volatile or can be rendered volatile through derivatisation [14-16]. It has the advantage that capillary gas chromatography is inherently a much higher resolution separation technique than liquid chromatography and thus there are fewer issues with the separation of isobaric or isomeric compounds. In addition the electron impact ionisation spectra produced by GC-MS provide a complex fingerprint which, when matched against library spectra, can differentiate between closely similar compounds such as isomers [1]. The limitation of GC-MS is that there are a large number of compounds within metabolomes which are not volatile or are unstable at the high temperatures required for GCMS. Thus this article focuses on how metabolites can be identified by using LCHRMS.

2. Identification in Mass Spectrometry

Although there are thousands of metabolites in biological systems the level of the challenge of identifying them can immediately be reduced if the interest is purely in identifying those that change in the system under investigation. The numbers of metabolites changing in response to for instance diseased vs healthy controls may be only tens of metabolites rather than thousands [16-30]. These are the compounds which hold the most interest with regard to identification since they might be used to support a particular hypothesis or diagnose a particular disease. The metabolomics standards initiative indicated different levels of identification of compounds in mass spectrometry [31, 32].

3. Elemental Composition

The most basic level of identification obtained using mass spectrometry is the molecular weight of a metabolite. When high resolution mass spectrometry is used the accurate molecular mass obtained can be assigned to a particular molecular formula. Experimentally measured masses are rarely exactly the same as a proposed molecular formula, so a formula will be assigned by software which has a mass deviation from the exact mass measured in ppm (ppm = (deviation of measured mass in atomic mass units/exact molecular weight)x10^6). The size of the deviation impacts on the confidence with which an elemental formula can be assigned to a mass. The degree of mass deviation depends on the type of ion separation method used to generate the mass spectrum. There are three major types of mass spectrometer used in high resolution...
measurements in metabolomics: Time of flight mass spectrometers (TOFs), ion cyclotron resonance mass spectrometers and Orbitraps. Mass accuracy performance is approximately as follows: TOF instruments ca 1-2 ppm, Orbitraps ca 1 ppm, ion cyclotron resonance ca 0.1 ppm [1, 34-40]. A more detailed discussion of these instruments can be found elsewhere [34, 39, 40]. In addition, optimal performance of an instrument depends on the instrument having been recently calibrated against compounds of known molecular weight and on the choice of suitable lock masses. A lock mass is an exact mass which is used to correct for any instrument drift during an analysis. Often in TOF instruments a compound which is to be used as a lock mass is continuously infused into the mass spectrometer ion source during a run. Alternatively the lock mass may be one or several background ions which are present throughout the analytical run such as ions generated from the solvents used in the chromatographic separation which are continuously being introduced into mass spectrometer source along with the ions of interest. When working with mass accuracy at < 3 ppm there is generally no difficulty in separating compounds with the same nominal mass. To get an idea of what ppm separation means in practical terms Table 1 lists compounds with masses between 132.05-132.12 with their ppm deviations from the preceding masses in the table. As can be seen in table 1, a high resolution mass spectrometer would have little trouble in distinguishing these isobaric compounds and the main problem, if for instance hydroxyproline was an important marker, would be in distinguishing it from its isomers.

Table 1. Isobaric compounds between 132.0-132.2 (taken from the Metlin database).

| Compound                              | Exact Mass | Molecular Formula  | Δppm |
|---------------------------------------|------------|--------------------|------|
| Iminospartic acid, oxosuccinamate     | 132.0291   | C₇H₇NO₃            | -    |
| N-acetylalanine,propionyl glycine,    | 132.0655   | C₇H₈NO₃            | 275  |
| hydroxyproline, aminolevulinic acid, |            |                    |      |
| oxoaminopentonic acid, N-acetyl-β-    |            |                    |      |
| alanine, glutamate semi-aldehyde,     |            |                    |      |
| Creatinine, guanidino propionic acid  | 132.0808   | C₁₃H₁₈NO₄          | 116  |
| Leucine, isoleucine, alanine betaine,  | 132.1019   | C₁₃H₁₈NO₃          | 160  |
| beta leucine, alloisoireucine,         |            |                    |      |
| aminocaproic acid.                    |            |                    |      |
| Guanidinobutanol, carboxyl putrescine | 132.1131   | C₁₃H₁₈NO₃          | 85   |

As the mass of a compound increases the number of possible combinations of elements which can add up to make its exact mass increases. The simplest way to evaluate the impact of the ppm deviation of the measured mass on correct assignment of elemental composition is to look at some examples. However, firstly we must consider which elements we should include in the search. Table 2 lists the exact masses of biologically relevant elements, which are covalently bound in naturally occurring organic compounds, along with their isotopes. The list could be slightly wider but selenium is so rare that it is not worth considering as a standard element to search for unless it is particularly abundant and the same is true of boron and silicon which may occur in specific biological systems. Halogens occur only rarely in biomolecules such as iodine in thyroxine, in specific biological systems or as xenobiotics in a particular biological system. Chlorine and bromine are instantly recognisable because of their characteristic isotope patterns. Metal ions are generally not covalently bound to organic molecules, there are obviously some exceptions, although they can contribute adducts to mass spectrometric data. Thus to keep it simple, for the purposes of this short review, it is a safe bet that the vast majority of compounds occurring in a biological system contain H, C, O, N, P, S, in that order of frequency of occurrence. Xenobiotics can confound this view but their occurrence is often idiosyncratic and thus they would not be picked up as a significant difference between a treated and control group unless of course, for instance, a drug treatment regimen was being studied.

Table 2. The biologically abundant elements and their isotopes.

| Element | Mass (%Abundance) | Mass (%Abundance) |
|---------|-------------------|-------------------|
| Electron | e (0.00055)       |                   |
| Hydrogen | H 1.00783 (100)   | H 2.01410 (0.0115)|
| Carbon   | 12C 12.00000 (100)| 13C 13.00335 (1.08)|
| Nitrogen | N 14.00307 (100)  | N 15.00011 (0.37) |
| Oxygen   | 16O 15.99491 (100)| 17O 16.99130 (0.21)|
| Phosphorus | 31P 30.97376 (100)|                   |
| Sulphur  | 32S 31.97207 (100)| 33S 33.96787 (5.52)|
|         |                   | 35S 35.96708 (0.02)|

4. The Assignment of Elemental Composition

Kind et al defined a formal set of rules for confirmation of the correct elemental composition for compounds according to their mass spectra [41]. Below these rules are restated simply for use with high resolution masses. These rules are not definitive but they present a simple first pass method for evaluating unknown metabolites.

1. Formula containing any combination of carbon, hydrogen, sulphur and oxygen, not necessarily all of these elements, cannot have an even MW in their protonated or deprotonated form (some compounds are fractionally (< 0.1 amu) below their nominal mass e.g. the negative ion of fructose bisphosphate (C₇H₁₈O₆P₂) has a mass of 338.9888 which for the purposes of this rule is regarded as 339).
2. Formulae containing odd numbers of nitrogen atoms have even MWs in their protonated or deprotonated forms.
3. Formulae containing even numbers of nitrogen atoms have odd MWs in their protonated or deprotonated forms.
4. Apart from for peptides it would be unusual to find more than 7 nitrogens in a structure.
5. It would be unusual for the number of oxygens to be more than one greater than the number of carbons. The number of nitrogens in a structure would be unlikely to exceed the number of carbons. The sum of nitrogens and oxygens would be unlikely to exceed the number of carbons. This rule does not always apply if there is one or more phosphorus atoms in the composition.
6. It would be unusual to find more than two sulphur or more than three phosphorus atoms in a structure.
7. One phosphorus requires at least four oxygens (usually found with 6 or more) in a formulae, two phosphorus atoms at least seven oxygens, three phosphorus atoms at least nine oxygen atoms.

8. Molecules containing both phosphorus and sulphur are relatively rare.

9. A degree of unsaturation (RDB equiv.) > 20 would be unusual for a low MW metabolite.

10. Assuming the instrument is tuned sufficiently well to give known marker metabolites accurate masses with < 1.5 ppm deviation, elemental compositions > three times the deviation for the first acceptable composition should be rejected. This rule should be applied in an iterative fashion if the first acceptable composition is rejected since it is absent from the databases.

Thus these rules can provide a framework for simply evaluating an elemental composition. It is not likely in practice that the sort of exercise described below would be carried out ahead of a database match. However, if the exact mass was not in the database then they could be useful. They are not perfect but neither are they complex. With these rules in mind it is possible to look at some examples. The restrictions applied to the formulae shown in table 3 in terms of number of elements allowed were C60 H100 N7 O20 P4 S2 with a RDB ≤ 20. The first example is for a compound with a measured at 744.08258 amu in positive ion mode on an Orbitrap Exactive. The high MW means that the possible variations in elemental composition are large.

Table 3. Identification of possible elemental compositions for m/z 744.08258.

| Hit No. | Dev. ppm | RDB | Elemental composition | Fails rule |
|--------|----------|-----|-----------------------|------------|
| 1      | 0.013    | 2   | C17 H40 O16 N4 P4 S2  | 3,4,5,8    |
| 2      | -0.027   | 20  | C33 H30 O14 P2 S     | 1,8        |
| 3      | 0.121    | 16.5| C27 H26 O20 N3 S     | Passes     |
| 4      | -0.202   | 12.5| C21 H29 O17 N7 P3    | Passes     |
| 5      | 0.215    | 17  | C25 H26 O17 N6 P2    | 3          |
| 6      | -0.296   | 12  | C23 H29 O20 N4 P S   | 3,5,8      |
| 7      | 0.430    | 6.5 | C21 H37 O16 N3 P3 S  | 8          |
| 8      | -0.444   | 15.5| C29 H33 O14 N P3 S   | 8          |
| 9      | 0.699    | 20  | C30 H32 O5 N6 P4 S2  | 3,7,8, 10 at the second iteration |

Thus there are two possible hits for this compound according to the rules. In practise automatic comparison against a database of accurate masses would be used to assign an identity to a metabolite. There are a number of databases which contain high resolution mass values of metabolites including the human metabolome database [42], KEGG [43], LipidMaps [44], ChemSpider (http://www.chemspider.com/) Metlin [45] and PubChem (http://pubchem.ncbi.nlm.nih.gov/). PubChem is the largest database of chemical compounds available but it contains many synthetic as well as naturally occurring compounds. Manually searching against PubChem returns no matches for hit 3. Searching the composition of hit 4 against PubChem returns 14 hits and only one of these corresponds to a naturally occurring metabolite, NADP+. Another example is a compound with a measured mass in positive ion mode of m/z 613.1598. This example is more challenging since the mass deviation for the metabolite is greater than the example above. The first match in PubChem is for hit 17 which matches oxidised glutathione (GSSG). Below this in the table there are no matches until formula 31 which matches a series of synthetic anti-tumour agents with complex non-biological structures. Hit 33 gives a match to a single compound in PubChem which is a polyphosphate sugar. In theory such structures could occur in nature but this is a synthetic compound. It is unlikely that one would often go through this laborious way of assigning a structure since database matching eliminates any compounds which are not known biomolecules. However, in the case of a complete unknown compound manual checking would be a component in deciding whether or not a hit seemed genuine. It is notable for the two examples given that the most frequently applied rules are the nitrogen rules 2 and 3.

5. Isotope Patterns

A high resolution spectrum contains additional information relating to the molecular ion in the form of an isotope pattern (see isotopes listed in table 2). The exactness of the correspondence of the isotope pattern to the theoretical pattern depends on the type of ion separation device used. TOF instruments give isotope ratios closer to the predicted level since there is no requirement to have a cut off level for low abundance ions. Ion trap instruments such as the Orbitrap have to limit trap fill due to space charge effects which produce interference between ions in the trap if it becomes too full. Thus traps have a cut off for low abundance ions to prevent overflow of the trap with ions which are essentially due to background noise. Software is available for correlating observed against theoretical isotope patterns and is either provided by vendors or available for free download [46]. The example of GSSG discussed above was obtained at high resolution on an Orbitrap but even at 50000 resolution for a large molecule like GSSG resolution between \(^{13}\)N, \(^{17}\)O and \(^{13}\)C peaks is not achieved and the ions sum into a single ion for the M+1 peak.

In theory GSSG (C20H33O12 N6S2) contains the following isotope patterns calculated from the abundances in table 1.

1. M+1 peak 20 x 1.08 (\(^{13}\)C) + 0.37 x 6 (\(^{15}\)N) + 0.21 x 12 (\(^{16}\)O) = 26.34%. In fact it is present at 19.9 % abundance due to the cut off level in the ion trap is thus not an exact match to theory.

2. More specific with regard to confirming identity is the presence of a peak at 615.1572 which is due to the \(^{34}\)S isotope (2x 4.52%) which is very characteristic of sulphur containing compounds. The other elements contribute very little at 2 amu higher than the molecular ion and thus the abundance of the [MH]\(^+\) +2 peak is in theory 9.04% but in the spectrum obtained from the sample it is 5.5%, the effect of the trap cut off becomes more marked for low intensity ions. However, the presence of this ion, despite the deviation from expected intensity, is very characteristic of a sulphur containing compound.

Isotope ratios can provide a quick check of whether or not a proposed formula makes sense. Figure 2 shows a comparison of the spectra of hippuric acid and glucosamine. These compounds are close in mass but have different numbers of carbon atoms and this can be immediately seen from the height of the \(^{13}\)C-isotope peak.
Table 4. Identification of possible elemental compositions for m/z 613.1598.

| Hit No. | Dev ppm | RDB | Elemental Composition | Fails Rule       |
|---------|---------|-----|-----------------------|------------------|
| 1       | -0.07   | 20  | C34 H31 O6 N S2       | 2                |
| 2       | -0.16   | 7.5 | C21 H36 O11 N4 P3     | Passes (Not in Pub Chem) |
| 3       | 0.23    | 11.5| C27 H33 O14 S         | Passes (Not in PubChem) |
| 4       | 0.24    | 17  | C26 H27 O9 N7 S       | 2                |
| 5       | -0.26   | 12.5| C22 H30 O9 N8 P S     | 8                |
| 6       | -0.28   | 7   | C23 H36 O14 N P S     | 2.8              |
| 7       | 0.34    | 12  | C25 H33 O11 N3 P2     | 2                |
| 8       | 0.36    | 17.5| C24 H27 O6 N10 P2     | 4.7              |
| 9       | -0.46   | 16  | C28 H34 O3 N5 P3 S    | 2.7              |
| 10      | -0.57   | 15.5| C30 H34 O6 N2 P S2    | 8                |
| 11      | 0.60    | 1.5 | C21 H44 O10 P3 S2     | 8                |
| 12      | 0.60    | 7   | C20 H38 O5 N7 P3 S2   | 2.8              |
| 13      | -0.78   | 8   | C18 H33 O9 N9 P2 S    | 2.8              |
| 14      | -0.78   | 2.5 | C19 H39 O14 N2 P2 S   | 8                |
| 15      | 0.80    | 3.5 | C14 H34 O11 N10 P S2  | 4.5,8            |
| 16      | 0.85    | 16.5| C29 H30 O11 N2 P      | Passes (Not in Pubchem) |
| 17      | -0.88   | 7.5 | C20 H33 O12 N6 S2     | Passes GSSG      |
| 18      | -1.06   | 16.5| C25 H31 O N10 P2 S2   | 4.7,8            |
| 19      | -1.08   | 11  | C26 H37 O6 N3 P2 S2   | 2.7,8            |
| 20      | 1.11    | 11.5| C24 H35 O5 N6 P2 S2   | 7.8              |
| 21      | -1.29   | 3.5 | C14 H36 O9 N10 P3 S   | 4.8              |
| 22      | 1.30    | 8   | C18 H31 O11 N9 S2     | 2.4              |
| 23      | -1.40   | 3   | C16 H36 O12 N7 P S2   | 2.8              |
| 24      | 1.40    | 3   | C17 H37 O13 N5 P2 S   | 2.8              |
| 25      | -1.58   | 6.5 | C22 H40 O6 N4 P3 S2   | 7.8              |
| 26      | 1.61    | 16  | C28 H32 O5 N5 P S2    | 2.8              |
| 27      | -1.65   | 13.5| C20 H25 O13 N10       | 4.5              |
| 28      | 1.73    | 11  | C27 H38 O7 N3 P3 S    | 2.8              |
| 29      | 1.73    | 16.5| C26 H32 O2 N8 P3 S    | 7.8              |
| 30      | -1.84   | 11.5| C27 H35 O12 P2        | Passes (not in PubChem) |
| 31      | -1.96   | 16.5| C28 H29 O10 N4 S      | Passes (in PubChem) |
| 32      | 2.02    | 2.5 | C20 H40 O15 P3        | Passes (in PubChem) |
| 33      | 2.53    | 12.5| C23 H31 O10 N6 P2     | Passes (not in PubChem) |
| 34      | 2.79    | 2   | C19 H42 O9 N3 P3 S2   | 2.8, 10 at second iteration |

6. Misidentification of Isotope Peaks

It is worth noting that isotope peaks can cause some false hits in terms of identification. Data extraction software can be used to filter out isotope peaks but this is a double edged sword since if the isotope peak matches a genuine compound then the genuine hit would be lost unless there was clear chromatographic separation. Returning to the GSSG 13C isotope peak which has a mass 615.1536, searched against a database this gave a match to within -1.6 ppm for cytidine monophosphate N-acetylneuraminic acid (KEGG entry C00128). There are probably numerous examples of this type of confusion. Two other examples are: Methyl dihydropterin (m/z 178.0723) due to the acetonitrile adduct of hypoxanthine and deoxyribose phosphate (m/z 215.0331) due to a 18O adduct of a hexose.

7. Identification of Isomers

The most common problem of identification in high resolution mass spectrometry is in the identification of isomers. There are two strategies available for isomer identification; they can either be separated chromatographically and matched against standards or they can be differentiated by fragmenting their molecular ions to produce a mass spectrum where the fragments can be used to characterise the
molecule of interest. The most reliable method for characterising isomers is to achieve chromatographic separation since the fragments derived from MS/MS or MS² are often not definitive and if the two isomers overlap chromatographically this will confuse the issue still further. However, setting up a chromatographic method to separate isomers relies on having authentic standards of the molecules of interest, although retention time prediction on the basis of proposed structure can also be helpful [47]. Figure 3 shows an extracted ion trace for dihydroxyacetone phosphate (DHP) and glyceraldehyde phosphate (GP) extracted from a mammalian cell culture on a ZICpHILIC column which produces separation of these two isomers. The additional peak in the trace with the same elemental composition is formed by low level fragmentation of fructose 1,6-diphosphate (F1,6P) in the mass spectrometer. F1,6P is the biosynthetic precursor of DHP and FP.

Figure 3. Extracted ion trace for dihydroxyacetone phosphate and glyceraldehyde phosphate extracted from mammalian cells separated on a ZICpHILIC column.

In fact DHP and GP can be distinguished by MS² since GP is able to readily eliminate water as DHP cannot (Figure 4).

8. Tandem MS and MS² Spectra

Distinguishing between isobaric compounds is much easier than distinguishing between isomers.

Figure 6 shows an extracted ion trace for metabolites in human urine in the range 245.0-245.2 amu. There are four major metabolites evident in this range. The molecular ion composition and MS² data for these compounds is shown in table 5. Two of the exact masses match compounds in Pubchem and other databases and as can be seen in table 5 they give completely different spectra. Many of the rules for fragmentation in mass spectrometry derive electron impact spectra. There have been no definitive rules determined for likely fragmentation pathways by tandem MS or MS² and it is only presumed that similar fragmentation rules apply as were determined for EI conditions. As can be seen in figure 7, where the fragmentations of biotin and uridine are rationalised, fragmentation is not necessarily straightforward. In the present case it is possible to explain the fragmentation but that is with knowing what the compounds are derived from a database match to the elemental composition. This would be less straightforward for a completely unknown structure. Thus mass spectra are often used as a fingerprint without any attempt at interpretation. However, with no database match and no authentic standard to match against a fingerprint is no use. Another problem is indicated in figure 8 where the mass spectra of uridine and pseudouridine in urine are compared. Both compounds are RNA metabolites but pseudouridine is much less abundant in RNA and thus at lower levels in urine. The exact mass of pseudouridine is very close to that of biotin which more or less overlaps with it chromatographically and the more abundant ions in
the spectrum are due to biotin. However, it is possible to see fragment ions at 227.0662 due to loss of water from pseudouridine and there is also a peak 113.03 due to loss of the ribose moiety. If pseudouridine was unknown it might be easy in the current example to confuse its MS² spectrum with that of biotin. The metabolite at 5.8 min did not give a match to the database and its fragment ion was not helpful with regard to understanding the structure, it might be that MS³ would help to elucidate the structure of the fragment ion but the structure is quite unusual in being highly unsaturated. The metabolite at 11.2 min did not return a sensible elemental composition within a ± 3 ppm window; however, on closer inspection it is the ¹³C-isotope peak of a metabolite at m/z 244.1542 which is probably pentenoylcarnitine since its shows loss of 59 amu in its MS² spectrum which is typical of carnitines.

Table 5. MS² data for compounds in the mass range 245.0-245.2 in human urine.

| Tr Min. | m/z   | Elemental Composition | Database Match | Fragment Ions |
|---------|-------|-----------------------|----------------|---------------|
| 5.8     | 245.0920 | C₉H₃N₂O₃ | -             | 170.0597 (C₉H₅NO) |
| 8.0     | 245.0953 | C₉H₁₆N₂O₆S | Biotin       | 227.0845 (C₉H₅N₂O₆S), 181.0929 (C₉H₅N₃O₆) |
| 9.9     | 245.0766 | C₆H₆N₂O₇ | Uridine      | 227.0662 (C₆H₆N₂O₇), 209.0555 (C₆H₅N₃O₅), 179.0451 (C₆H₅N₃O₅), 155.0451 (C₆H₅N₂O₅) |
| 11.2    | 245.1575 | -                    | -             | 186.0840 |

9. Tandem MS and MS³ in Metabolomics Studies

Many mass spectrometry based metabolomics studies have based their identification of metabolites on the combination of assignment of elemental composition to a metabolite peak and the matching of retention times to the retention times of standards. This is quite reasonable since this is a very specific method already. However, sometimes standards are not available and if a marker compound is significant it is important to characterise it by using tandem MS or MS³. Many papers used fragmentation as additional confirmation of compound identity [16-30] but in these papers there is often no discussion the MS/MS spectra since standards are available. The Metlin data base has recorded MS/MS spectra for many naturally occurring metabolites and xenobiotics (http://metlin.scripps.edu) obtained on an Agilent QTOF instrument. MS/MS spectra vary a great deal according to the instrument used, the collision energy used, the collision gas used and the collision gas pressure. More extensive interpretation of mass spectra is required where there is no standard available. There are surprisingly few papers metabolomics papers, studying higher organisms, where the details of structure elucidation of marker compounds have been reported and even many of these do not give full details such collision energy and the gas used for CID. Table 6 summarises some recent studies where fragmentation was used to elucidate the structure and details of the fragmentation patterns observed were given.
If MS/MS or MS² spectra do not provide complete structure elucidation it is possible to use MS^n on ion trap instruments to fragment the fragment ions produced in MS² experiments further. Of course this may not always work since the fragment ions produced at the first iteration tend to be stable ions. There is a current trend to move towards MS^n identification using spectral trees [62-64] but this is perhaps overkill for the identification of routine metabolites where standards are available, however, it is useful where a complete unknown metabolite is being elucidated.

**10. Other Factors Supporting Compound Identification**

Studies where metabolite hits fall into a single or into closely related metabolic pathways generate greater confidence in the identification of the metabolites within those pathways. Random hits standing in isolation from a defined metabolic pathway are less satisfactory. There are examples of metabolomics studies where the metabolites identified as being changed are metabolically related to each other [16, 64-67] but there are many more where the metabolite changes are seemingly random. Another strategy for identifying metabolites is to predict metabolites in a series. For example phenylacetyl glutamine is an abundant urinary metabolite but no other fatty acid conjugates of this type had been described. It was possible explain a number of metabolites in urine through predicting that other conjugates in this series would be present by simply making a synthetic list of metabolites with the appropriate exact mass by combining fatty acid acyl moieties and glutamine [68].

**II. Conclusion**

In this short review I have tried to simplify the process of metabolite ID by breaking it down into discrete steps. When using high resolution mass spectrometry to identify metabolites in conjunction with a database search, most often the major challenges

| Nature of Study                                                                 | Conditions used/Comments                                                                 | Ref.                |
|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|---------------------|
| Comparison of xanthuria type I and xanthuria type II                            | LTQ Orbitrap. MS² helium collision gas. Collision energy 35V. HILIC separation. Four products of aldehyde oxidase were characterised based on the accurate masses of their fragment ions. Interpretation of fragment ions provided. | [50]               |
| Metabolic effects of activation of pregnane X receptor.                         | Waters QTOF. RP separation. α-carboxethyl hydroxysrochrome β-D-glucoside identified as a novel metabolite of vitamin E attenuated by activation of pregnane X receptor. An authentic standard was synthesised. | [51]               |
| Diagnostic markers for ovarian cancer in human serum.                           | Waters QTOF, preparative HPLC and Bruker FT-ICR. Initial measurements made using RP separation. The structure 27-nor-5β-cholestan-3,7,12,24,25 pentol glucuronide was elucidated by MS/MS, high accuracy mass measurement and hydrolysis of the glucuronide followed by comparison with a standard. | [29]               |
| Profiles of non-polar metabolites in rat and mouse liver altered in response to alcohol. | Shimadzu IT TOF. RP separation. Several fatty acids, fatty acid esters and cholesterol identified as markers of alcohol consumption. Details given for MS/MS spectra of markers. Comparison made against authentic standards. | [52]               |
| Human serum biomarkers of Onchoeceriasis.                                       | Agilent QTOF with CID 20V and RP separation and Bruker FT-ICR. Fourteen biomarkers observed and structures partially or completely determined by MS/MS and high resolution MS. | [53]               |
| Biomarkers of the effects pressure in divers.                                   | Agilent QTOF and RP separation. Over 100 metabolites were altered. Tables provided with their major fragment ions. | [54]               |
| Characterisation of extracellular metabolites of Chinese hamster ovary cells.   | LTQ Orbitrap and Waters Synapt instrument with CID at 6 or 20V and argon collision gas. RP separation. The Orbitrap provided diagnostic ions for a series of glutamyl peptides. The Synapt system was used to isolate glutamyl phenylalanine from co-eluting isobaric compounds which produced interference in its MS/MS spectrum. | [55]               |
| Profiling of metabolites in human CSF.                                          | Agilent TOF 6210, 20V. RP separation. Twelve metabolites shared between human plasma and CSF were characterised by MS. Tables provided with their major fragment ions. | [56]               |
| Serum biomarkers of hepatocellular carcinoma.                                  | Waters QTOF and RP separation. Details given from MS/MS structure verification of seven marker compounds. | [57]               |
| Identification of metabolites in human urine.                                 | LTQ Orbitrap, 20V CID. RP and PFP column used for separation. Compounds annotated using standards and MS/MS. Details of MS/MS provided in supplementary tables. | [58]               |
| Metabolic map of procainamide metabolism in mice and humans.                    | Waters QTOF. RP separation. Thirteen urinary metabolites of procainamide including nine novel metabolites were characterised by using MS/MS data. | [59]               |
| Phenotyping of toxicity of Chuanwu in Wistar rats.                             | Waters QTOF Micro Synapt. RP separation. The MS/MS spectra of a range of novel biomarkers of toxicity are described. | [60]               |
| Determination of glycosphingolipids markers of Fabry’s disease.                | Waters QTOF CID 20-35V. RP and HILIC separation. MS/MS was used to characterise a series of glycosylated sphingosine markers compounds. | [61]               |
are chromatographic rather than mass spectrometric since it is important to ensure that isomeric compounds are separated. It is important to distinguish challenges of working with metabolites in metazoan systems from the more complex challenges of identifying metabolites in plants. The range of metabolites in metazoan systems is much more restricted than that in plants. However, low levels of unknown metabolites are likely to remain difficult to identify since the only definitive technique for full structure elucidation is NMR which requires mg amounts of material, although the use of capillary NMR tubes can reduce this. Surveying the literature there are not that many examples where an unknown metabolite highlighted in a metabolomics screen has been identified by mass spectrometry. This is likely to change as applications of metabolomics increase. However, the lack of clear examples MS/MS or MS² structural ID experiments in metabolomics in metazoans makes it difficult to assess the effectiveness of these methods. It can be particularly difficult to get useful information when dealing with compounds with low intensity signals where clear fragmentation patterns may not be obtained.

Citation
Watson DG (2013) A Rough Guide to Metabolite Identification Using High Resolution Liquid Chromatography Mass Spectrometry in Metabolomic Profiling in Metazoans Computational and Structural Biotechnology Journal. 4 (5): e201301005. doi: http://dx.doi.org/10.5936/csbj.201301005

References
1. Dunn WB, Erban A, Weber RJM, Creek DJ, Brown M, et al (2012). Mass appeal: metabolite identification in mass spectrometry focused untargeted metabolomics. Metabolomics. Published on-line.
2. Brown M, Wedge DC, Goodacre R, Kell DB, Baker PN, et al (2011) Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics 27: 1108-1112.
3. Courant F, Royer A-L, Chereau S, Morvan M-L, Monteau F, et al (2012) Implementation of a semi-automated strategy for the annotation of metabolomic fingerprints generated by liquid chromatography-high resolution mass spectrometry from biological samples. The Analyst 137: 4958-4967.
4. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, et al (2011) Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols 6: 1060-1083.
5. Wishart DS (2011) Advances in metabolite identification. Bioanalysis 3: 1769-1782.
6. Brown M, Dunn WB, Dobson P, Patel Y, Winder CL, et al (2009) Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics. Analyst 134: 1322-1332.
7. Dunn WB, Broadhurst D, Atherton HJ, Goodacre R, Griffin JL (2011) Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society Reviews 40: 387-426.
8. Garcia-Canaveras JC, Teresa Donato M, Castell JV, Lahez A (2012) Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. Journal of Lipid Research 53: 2231-2241.
9. Sun T, Wetzler SJ, Johnson ME, Surlow BA, Patton-Vogt J (2012) Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the quantification of lipid-related extracellular metabolites in Saccharomyces cerevisiae. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 897: 1-9.
10. Stoop MP, Coulier L, Rosenthal T, Shi S, Smolinska AM, et al (2010) Quantitative Proteomics and Metabolomics Analysis of Normal Human Cerebrospinal Fluid Samples. Molecular & Cellular Proteomics 9: 2063-2075.
11. Wei R, Li G, Seymour AB (2010) High-Throughput and Multiplexed LC/MS/MSRM Method for Targeted Metabolomics. Analytical Chemistry 82: 5527-5533.
12. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK (2009) Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 877: 1229-1239.
13. Sawada Y, Akiyama K, Sakata A, Kuwahara A, Otsuki H, et al (2009) Widely Targeted Metabolomics Based on Large-Scale MS/MS Data for Elucidating Metabolite Accumulation Patterns in Plants. Plant and Cell Physiology 50: 37-47.
14. Koeo MM, Jellemma RH, van der Gref J, Tas AC, Hankemeier T (2011) Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics 7: 307-328.
15. Begley P, Francis-McIntyre S, Dunn WB, Broadhurst DI, Halsall A, et al (2009) Development and Performance of a Gas Chromatography-Time-of-Flight Mass Spectrometry Analysis for Large-Scale Nontargeted Metabolomic Studies of Human Serum. Analytical Chemistry 81: 7038-7046.
16. Chen Q, Park H-C, Goligorsky MS, Chander P, Fischer SM, et al (2012) Untargeted Plasma Metabolite Profiling Reveals the Broad Systemic Consequences of Xanthine Oxidoreductase Inactivation in Mice. Plos One 7.
17. Lu Y, Wang C, Chen Z, Zhao H, Chen J, et al (2012) Serum metabolomics for the diagnosis and classification of myasthenia gravis. Metabolomics 8: 704-713.
18. Sun J, Shannon M, Ando Y, Schnackenberg IK, Khan NA, et al (2012) Serum metabolomic profiles from patients with acute kidney injury: A pilot study. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 893: 107-113.
19. Gu Y, Lu C, Zha Q, Kong H, Lu X, et al (2012) Plasma metabolomics study of rheumatoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry. Molecular Biosystems 8: 1535-1543.
20. Noga MJ, Dane A, Shi S, Attali A, van Aken H, et al (2012) Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 8: 253-263.
21. Brockmoeller SF, Bucher E, Mueller BM, Budziesz J, Hilvo M, et al (2012) Integration of Metabolomics and Expression of Glycolyl-3-phosphate Aclyltransferase (GPAM) in Breast Cancer-Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling. Journal of Proteome Research 11: 850-860.
22. van der Kloet FM, Tempels FWA, Ismail N, van der Heijden R, Kasper PT, et al (2012) Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics 8: 109-119.
23. Zhang J, Bowers J, Liu L, Wei S, Gowda GAN, et al (2012) Esophageal Cancer Metabolite Biomarkers Detected by LC-MS and NMR Methods. Plos One 7.
24. Mataruocchi E, Baraldi E, Guillou C (2012) Metabolomics applied to urine samples in childhood asthma; differentiation between
asthma phenotypes and identification of relevant metabolites. Biomedical Chromatography 26: 89-94.
25. Akesson L, Trygg J, Fuller JM, Madsen R, Gabrielson J, et al. (2011) Serum metabolite signature predicts the acute onset of diabetes in spontaneously diabetic congenic BB rats. Metabolomics 7: 593-603.
26. Garcia-Canaveras JC, Teresa Donato M, Castell JV, Lahoz A (2011) A Comprehensive Untargeted Metabonomic Analysis of Human Steatotic Liver Tissue by RP and HILIC Chromatography Coupled to Mass Spectrometry Reveals Important Metabolic Alterations. Journal of Proteome Research 10: 4825-4834.
27. Dai W, Wei C, Kong H, Jia Z, Han J, et al. (2011) Effect of the traditional Chinese medicine tongxinluo on endothelial dysfunction rats studied by using urinary metabolomics based on liquid chromatography-mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 56: 86-92.
28. Ruiz-Aracama A, Peijnenburg A, Kleinjans J, Jennen D, van Delft J, et al. (2011) An untargeted multi-technique metabolomics approach to studying intracellular metabolites of HepG2 cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Bmc Genomics 12.
29. Chen J, Zhang X, Cao R, Lu X, Zhao S, et al. (2011) Serum 27-nor-5 beta-Cholesterol-3,7,12,24,25 Pentol Glucuronide Discovered by Metabolomics as Potential Diagnostic Biomarker for Epithelium Ovarian Cancer. Journal of Proteome Research 10: 2625-2632.
30. Lin L, Huang Z, Gao Y, Yan X, Xing J, et al. (2011) LC-MS based serum metabolomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. Journal of Proteome Research 10: 1396-1405.
31. Kind T, Wohlgemuth G, Lee DY, Lu Y, Palazoglu M, et al. (2009) FiehnLib: Mass Spectral and Retention Index Libraries for Metabolomics Based on Quadrupole and Time-of-Flight Gas Chromatography/Mass Spectrometry. Analytical Chemistry 81: 10038-10048.
32. Fiehn O, Robertson D, Griffin J, van der Werf M, Nikolau B, et al. (2007) The metabolomics standards initiative (MSI). Metabolomics 3: 175-178.
33. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, et al. (2007) Proposed minimum reporting standards for chemical analysis. Metabolomics 3: 211-221.
34. Xiao JF, Zhou B, Ressom HW (2012) Metabolite identification and quantitation in LC-MS/MS-based metabolomics. Trac-Trends in Analytical Chemistry 32: 1-14.
35. Himmelsbach M (2012) 10 years of MS instrumental developments - Impact on LC-MS/MS in clinical chemistry. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences 883: 3-17.
36. Theodoridis GA, Gika HG, Want EJ, Wilson ID (2012) Liquid chromatography-mass spectrometry based global metabolite profiling: A review. Analytica Chimica Acta 711: 7-16.
37. Lai L, Michopoulos F, Gika H, Theodoridis G, Wilkinson RW, et al. (2010) Methodological considerations in the development of HPLC-MS methods for the analysis of rodent plasma for metabolomic studies. Molecular Biosystems 6: 108-120.
38. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, et al. (2010) Global metabolic profiling procedures for urine using UPLC-MS. Nature Protocols 5: 1005-1018.
39. Kind T, Fiehn O (2010) Advances in structure elucidation of small molecules using
40. mass spectrometry. Bioanal Rev. 2:23-60
41. Kamleh MA, Dow JAT, Watson DG (2009) Applications of mass spectrometry in metabolomic studies of animal model and invertebrate systems. Briefings in Functional Genomics & Proteomics 8: 28-48.
42. Kind T, Fiehn O (2007) Seven Golden Rules for heuristic filtering of molecular formulas obtained by accurate mass spectrometry. Bmc Bioinformatics 8.
43. Wishart DS, Knox C, Guo AC, Eisner R, Young N, et al. (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Research 37: D603-D610.
44. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research 27: 29-34.
45. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, et al. (2007) LMSD: LIPID MAPS structure database. Nucleic Acids Research 35: D527-D532.
46. Smith CA, O’Malie G, Want EJ, Qin C, Trauger SA, et al. (2005) METLIN - A metabolite mass spectral database. Therapeutic Drug Monitoring 27: 747-751.
47. Pluskal T, Uehara T, Yanagida M (2012) Highly Accurate Chemical Formula Prediction Tool Utilizing High-Resolution Mass Spectra, MS/MS Fragmentation, Heuristic Rules, and Isotope Pattern Matching. Analytical Chemistry 84: 4396-4403.
48. Creek DJ, Jankevics A, Breitling R, Watson DG, Barrett MP, et al. (2011) Toward Global Metabolomics Analysis with Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry: Improved Metabolite Identification by Retention Time Prediction. Analytical Chemistry 83: 8703-8710.
49. Antonio C, Larson T, Gilday A, Graham I, Bergstrom E, et al. (2007) Quantification of sugars and sugar phosphates in Arabidopsis thaliana tissues using porous graphitic carbon liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography A 1172: 170-178.
50. Burgess K, Creek D, Dewsbury F, Cook K, Barrett MP (2011) Semi-targeted analysis of metabolites using capillary-flow ion chromatography coupled to high-resolution mass spectrometry. Rapid Communications in Mass Spectrometry 25: 3447-3452.
51. Peretz H, Watson D, Blackburn G, Zhang T, Lagziel A, et al. (2012) Urine metabolomics reveals novel physiologic functions of human aldehyde oxidase and provides biomarkers for typing xanthinuria. Metabolomics 8: 951-959.
52. Cho J-Y, Kang DW, Ma X, Ahn SH, Krausz KW, et al. (2009) Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. Journal of Lipid Research 50: 924-937.
53. Lofrus N, Barnes A, Ashton S, Michopoulos F, Theodoridis G, et al. (2011) Metabonomic Investigation of Liver Profiles of Nonpolar Metabolites Obtained from Alcohol-Dosed Rats and Mice Using High Mass Accuracy Msn Analysis. Journal of Proteome Research 10: 705-713.
54. Denery JR, Nunes AAK, Hixon MS, Dickerson TJ, Janda KD (2010) Metabolomics-Based Discovery of Diagnostic Biomarkers for Onchocerciasis. Plos Neglected Tropical Diseases 4.
55. Ciborowski M, Javier Ruperez F, Paz Martinez-Alcazar M, Angulo S, Radziwon P, et al. (2010) Metabolic Approach with LC-MS Reveals Significant Effect of Pressure on Diver’s Plasma. Journal of Proteome Research 9: 4131-4137.
56. Chong WPK, Goh LT, Reddy SG, Yusufi FNK, Lee DY, et al. (2009) Metabolomics profiling of extracellular metabolites in recombinant Chinese Hamster Ovary fed-batch culture. Rapid Communications in Mass Spectrometry 23: 3763-3771.
57. Crews B, Wikoff WR, Patti GJ, Woo HK, Kalistak E, et al. (2009) Variability Analysis of Human Plasma and Cerebral Spinal Fluid
Reveals Statistical Significance of Changes in Mass Spectrometry-Based Metabolomics Data. Analytical Chemistry 81: 8538-8544.

Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, et al. (2012) Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Analytica chimica acta 743C: 90-100.

Roux A, Xu Y, Helier J-F, Olivier M-F, Ezan E, et al. (2012) Annotation of the human adult urinary metabolome and metabolite identification using ultra high performance liquid chromatography coupled to a linear quadrupole ion trap-orbitrap mass spectrometer. Analytical Chemistry 84: 6429-6437.

Li F, Patterson AD, Krausz KW, Dick B, Frey FJ, et al. (2012) Metabolomics reveals the metabolic map of procainamide in humans and mice. Biochemical Pharmacology 83: 1435-1444.

Dong H, Zhang A, Sun H, Wang H, Lu X, et al. (2012) Ingenuity pathways analysis of urine metabolomics phenotypes toxicity of Chuanwu in Wistar rats by UPLC-Q-TOF-HDMS coupled with pattern recognition methods. Molecular Biosystems 8: 1206-1221.

Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, et al. (2012) Urinary Globotriaosylsphingosine-Related Biomarkers for Fabry Disease Targeted by Metabolomics. Analytical Chemistry 84: 2745-2753.

van der Hooft JJJ, Vervoort J, Bino RJ, de Vos RCH (2012) Spectral trees as a robust annotation tool in LC-MS based metabolomics. Metabolomics 8: 691-703.

Ridder L, van der Hooft JJJ, Verhoeven S, de Vos RCH, van Schaik R, et al. (2012) Substructure-based annotation of high-resolution multistage MSn spectral trees. Rapid Communications in Mass Spectrometry 26: 2461-2471.

Kasper PT, Rojas-Cherto M, Mistrik R, Reijmers T, Hankemeier T, et al. (2012) Fragmentation trees for the structural characterisation of metabolites. Rapid Communications in Mass Spectrometry 26: 2275-2286.

Tsutsui H, Maeda T, Toyoko T, Min JZ, Inagaki S, et al. (2010) Practical Analytical Approach for the Identification of Biomarker Candidates in Prediabetic State Based upon Metabonomic Study by Ultraperformance Liquid Chromatography Coupled to Electrospray Ionization Time-of-Flight Mass Spectrometry. Journal of Proteome Research 9: 3912-3922.

Al Bratty M, Hobani Y, Dow JAT, Watson DG (2011) Metabolomic profiling of the effects of allopurinol on Drosophila melanogaster. Metabolomics 7: 542-548.

Kamleh MA, Hobani Y, Dow JAT, Watson DG (2008) Metabolomic profiling of Drosophila using liquid chromatography Fourier transform mass spectrometry. Febs Letters 582: 2916-2922.

Zhang T, Creek DJ, Barrett MP, Blackburn G, Watson DG (2012) Evaluation of Coupling Reversed Phase, Aqueous Normal Phase, and Hydrophilic Interaction Liquid Chromatography with Orbitrap Mass Spectrometry for Metabolic Studies of Human Urine. Analytical Chemistry 84: 1994-2001.

Keywords:
Elemental composition, mass deviation, isotope peaks, MS²

Competing Interests:
The authors have declared that no competing interests exist.

© 2013 Watson.
Licensee: Computational and Structural Biotechnology Journal.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited.

What is the advantage to you of publishing in Computational and Structural Biotechnology Journal (CSBJ) ?
1. Easy 5 step online submission system & online manuscript tracking
2. Fastest turnaround time with thorough peer review
3. Inclusion in scholarly databases
4. Low Article Processing Charges
5. Author Copyright
6. Open access, available to anyone in the world to download for free

WWW.CSBJ.ORG

Computational and Structural Biotechnology Journal | www.csbj.org